Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10017815 | 0.80 | — | — | |
| SCHEMBL51157 | 0.73 | — | — | |
| SCHEMBL14007344 | 0.71 | — | — | |
| SCHEMBL5719 | 0.71 | — | — | |
| SCHEMBL6041979 | 0.71 | — | — | |
| SCHEMBL924218 | 0.69 | — | — | |
| SCHEMBL2775798 | 0.69 | ALDH1A1 (0.35) | — | |
| SCHEMBL18354562 | 0.68 | MAPK1 (0.42) | — | |
| SCHEMBL14968999 | 0.68 | MAPK1 (0.42) | — | |
| SCHEMBL10456912 | 0.68 | MAPT (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1391451-B1 | 2-IMINOPYRROLIDINE DERIVATES | EISAI R&D MAN CO LTD (JP) | 2011-11-23 | — | — | EP | disclosed |
| US-20090215795-A1 | CYCLIC AMIDINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-08-27 | — | — | US | disclosed |
| EP-1391456-B1 | 2-IMINOIMIDAZOLE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2009-07-22 | — | — | EP | disclosed |
| EP-1386912-B1 | CYCLIC AMIDINE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2009-03-18 | — | — | EP | disclosed |
| US-7476688-B2 | Cyclic amidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-13 | — | — | US | disclosed |
| US-7304083-B2 | 2-iminoimidazole derivatives (2) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-12-04 | — | — | US | disclosed |
| US-7244730-B2 | 2-iminopyrrolidine derivatives | EISAI CO., LTD (JP) | 2007-07-17 | — | — | US | disclosed |
| EP-1614680-A2 | Process for preparing 2-iminopyrrolidine derivatives | Eisai Co., Ltd. (JP) | 2006-01-11 | — | — | EP | disclosed |
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| US-20040254376-A1 | Cyclic amidine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-12-16 | — | — | US | disclosed |
| US-20040242627-A1 | 2-Iminoimidazole derivatives (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-1394152-A1 | 2-IMINOIMIDAZOLE DERIVATIVES (1) | Eisai Co., Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
| EP-1391456-A1 | 2-IMINOIMIDAZOLE DERIVATIVE (2) | Eisai Co., Ltd. (JP) | 2004-02-25 | — | — | EP | disclosed |
| EP-1391451-A1 | 2-IMINOPYRROLIDINE DERIVATES | Eisai Co., Ltd. (JP) | 2004-02-25 | — | — | EP | disclosed |
| EP-1386912-A1 | CYCLIC AMIDINE DERIVATIVE | Eisai Co., Ltd. (JP) | 2004-02-04 | — | — | EP | disclosed |
| EP-0736018-B1 | 4,5-DIARYLOXAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-07-05 | — | — | EP | disclosed |
| US-6025375-A | INHIBITORY ACTIVITY ON PLATELET AGGREGATION, VASODILATING ACTIVITY, ANTIHYPERTENSIVE ACTIVITY OR THE LIKE AND ARE PROSTAGLANDIN I.SUB.2 AGONISTS, | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-02-15 | — | — | US | disclosed |
| EP-0736018-A1 | 4,5-DIARYLOXAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-09 | — | — | EP | disclosed |
| WO-1995017393-A1 | 4,5-DIARYLOXAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | CYP2C9 415/4885TSHR 909/4885 |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | CYP2C9 406/4885TSHR 911/4885 |
| US-20040242627-A1 | 2-Iminoimidazole derivatives (1) | H1-2, H1-0, H1-3 | CYP2C9 798/4885TSHR 1625/4885 |
| US-20040254376-A1 | Cyclic amidine derivative | ARGLU1, ARG1, PRMT1 | CYP2C9 2149/4885TSHR 265/4885 |
| US-20090215795-A1 | CYCLIC AMIDINE DERIVATIVES | H1-10, H1-3, H1-4 | CYP2C9 971/4885TSHR 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.